
IVIG、SCIG 和 mABs疗法

IVIG、SCIG 和 mABs疗法
根据临床经验,在我们的患者群体中,从 IVIG 转向 SCIG 显然是更好的趋势。
单克隆抗体(mABs)是治疗长期慢性疾病、Vac 后疾病和慢性疾病的一个新领域。这些疾病涉及复杂的免疫失调和炎症反应。
IVIG 和 SCIG 是一种从集合人血浆中提取的浓缩免疫球蛋白制剂。
目前的官方适应症包括慢性病和许多病毒后遗症:心肌炎和心包炎、小纤维神经病,以及败血症等急性/严重疾病。
针对免疫反应特定成分设计的单克隆抗体为干预提供了另一种途径。
目前正在研究免疫球蛋白(IVIG/SCIG)和单克隆抗体(mABs)恢复免疫平衡的潜力。
Here is a current study regarding the use of IVIG in Long Covid/Small Fiber Neuropathy: https://www.neurology.org/doi/10.1212/NXI.0000000000200244
传闻:mABs 是针对特定菌株设计的,而 IVIG/SCIG 不是。据我们所知,目前还没有长Covid/后Vac患者在接受SCIG或mABs治疗后病情永久恶化的报道。我们的医疗团队观察到的唯一在 IVIG 治疗后病情暂时恶化的患者是症状类似于头痛并向下扩展到颈部的患者。
许多 mABs 已停产或价格高昂,因此 SCIG 的使用已成为主流。随着 Evusheld 和 Kavigale(即将上市)的上市,这种情况正在发生变化。
重要的是
mABs/SCIGs/IVIGs/Antiretrovirals: e.g. Evusheld, Hizentra, HyQvia, Kavigale, Truvada
After clearing of treating doctors and advisors only, pre-order time 2-3 weeks (involves cold chain logistics) – please check availability (varies by product, lifecycle stage and manufacturer) with our team
IVIG vs SCIG – the same ingredient but different administration
行政管理:
- IVIG is infused into a vein over 1–4 hours. It causes a rapid rise in serum immunoglobulin (IG) levels, peaking within 15 minutes, followed by a drop over 48 hours.
- SCIG is injected under the skin into fatty tissue and is absorbed slowly into the bloodstream, resulting in more stable IG levels without peaks and troughs.
功效:
- Both methods in theory are equally effective. From clinical experience the trend in our patient population is towards SCIG with clearly better results.
SCIG - 优势
- Fewer systemic side effects (e.g., headache, fever, nausea).
- More consistent IG levels (no peaks or troughs).
- Self-administered at home; no IV access required.
- Greater flexibility in scheduling.
- Ideal for patients with primary immunodeficiency (PI) or poor venous access.
- Better tolerated in patients with prior IVIG side effects.
- 降低感染风险--无需中央管路或住院治疗。
IVIG – Advantages
- Faster onset of action.
- Suitable for (expensive) high-dose regimens (e.g., 2 g/kg).
- Typically given in a clinic or at home by a nurse
- Less frequent needle use.
- Fewer local injection-site reactions.
- Preferred for patients uncomfortable with self-injection or frequent needle use.